Home >
Medicine Info >
Peg-Adrim 50 Injection
Loading interface...

Peg-Adrim 50 Injection

Manufactured byFRESENIUS KABI INDIA PVT LTD
ContainsDoxorubicin (Pegylated Liposomal)
Description
Peg-Adrim 50 Injection is an anticancer medicine which is used for the treatment of cancers of the blood and ovaries (female reproductive organ). It is also used for the treatment of Kaposi's sarcoma (a type of cancer that causes lesions to grow below the surface of the skin, lymph nodes, membranes of the mouth, eyes, nose, etc.) in human immunodeficiency virus (HIV) infected patients who have not adequately responded to other anticancer medications. This medicine is a formulation of doxorubicin in polyethylene glycol (PEG) coated liposomes which increases blood circulation time of the medicine by preventing its degrading inside the cells or tissues and also reduces the toxic effects as compared to the conventional doxorubicin.
QUICK LINKS:
Side effectsConcernsUsageRelated products

Side effects

Major & minor side effects for Peg-Adrim 50 Injection

  • Pain at the injection site
  • Nausea and Vomiting
  • Rectal or vaginal bleeding
  • Headache
  • Numbness of hands or feet
  • Skin rash or itching
  • Dizziness
  • Hair loss
  • Muscle pain
  • Diarrhea

Uses of Peg-Adrim 50 Injection

What is it prescribed for?

  • AIDS-Related Kaposi's Sarcoma
  • Ovarian Cancer
  • Breast cancer
  • Multiple Myeloma
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The amount of time required for this medicine to show its action is not clinically established.
  • How long do the effects of this medicine last?
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit-forming tendencies were reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

Allergy

This medicine is not recommended for use if you have a known allergy to Pegylated liposomal doxorubicin or any other inactive ingredients present along with it.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before receiving this medicine.
General warnings

Blood cell count

This medicine is known to lower the white blood cell count (neutrophils) in patients with risk factors such as pre-existing diseases or medicines. Close monitoring of blood cell count is necessary. Do not start the treatment if the blood cell count is low.

Secondary oral cancers

This medicine is known to increase the risk of secondary cancers, most frequently in the mouth. Close monitoring of symptoms like mouth ulcers, bleeding is necessary. The treatment should be discontinued if secondary cancer develops.

Risk of infections

Use of this medicine may weaken the immune system and may make you more vulnerable to infections. It is advised that you avoid coming in contact with people suffering from an infection while receiving this medicine.

Liver impairment

This medicine should be used with caution in patients with liver impairment due to the increased risk of severe adverse effects. Close monitoring of liver function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Missed Dose

Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low. However, it is advised to contact the doctor immediately if you miss a scheduled dose of this medicine.

Overdose

Since this medicine is administered in the hospital setting by a qualified healthcare professional, the likelihood of an overdose is very less. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Live attenuated vaccines and related products

Adalimumab

Moxifloxacin

Certolizumab

Disease interactions

Disease

Information not available.
Food interactions
Information not available.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine
Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

Does not cause sleepiness

How it works
It works by stopping the growth of cancer cells by inhibiting DNA synthesis.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Antibiotics/antineoplastics, Anthracycline antineoplastic antibiotic

Schedule

Schedule H

[Internet]. Bccancer.bc.ca. 2019 [cited 26 March 2019]. Available from:

http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Doxorubicin%20pegylated%20liposomal_monograph.pdf

[Internet]. Ncbi.nlm.nih.gov. 2019 [cited 26 March 2019]. Available from:

https://www.ncbi.nlm.nih.gov/pubmed/11405181

[Internet]. Ncbi.nlm.nih.gov. 2019 [cited 26 March 2019]. Available from:

https://www.ncbi.nlm.nih.gov/pubmed/18701868

[Internet]. Ncbi.nlm.nih.gov. 2019 [cited 26 March 2019]. Available from:

https://www.ncbi.nlm.nih.gov/pubmed/15717735

Internet]. Janssen.com. 2019 [cited 26 March 2019]. Available from:

http://www.janssen.com/australia/sites/www_janssen_com_australia/files/prod_files/live/caelyx_pi.pdf
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 24 May 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.